Chrysophanol Alleviates Metabolic Syndrome by Activating the SIRT6/AMPK Signaling Pathway in Brown Adipocytes

Xueying Liu, Zehong Yang, Huixuan Li, Wen Luo, Wentao Duan, Junmei Zhang, Zhangzhi Zhu, Min Liu, Saimei Li, Xiaoyi Xin, Hao‐Xiang Wu, Shaoxiang Xian, Meijing Liu, Changhui Liu, Chuangpeng ShenOxidative 2020 · DOI

TL;DR

This study reveals that chrysophanol, a compound from traditional Chinese medicine, combats obesity by activating the SIRT6/AMPK pathway. This activation promotes the conversion of white fat to brown fat, increasing energy expenditure and improving metabolic health in obese mice.

What Problem Does This Paper Address?

Obesity is a major global health challenge linked to insulin resistance, diabetes, and cardiovascular disease. While lifestyle changes are key, effective pharmacological interventions are still sought. Adipose tissue, once thought to be solely for fat storage, is now recognized for its role in energy metabolism, particularly brown and beige adipocytes, which generate heat. However, the precise molecular mechanisms by which compounds can leverage these thermogenic pathways to combat obesity remain an active area of research. This paper investigates chrysophanol, a known bioactive compound, and its potential to mitigate obesity by targeting the SIRT6/AMPK signaling axis in adipose tissue.

Methods

The researchers employed a multi-pronged approach:

  • In vitro studies: They used 3T3-L1 cells, a standard model for adipocyte differentiation, to investigate chrysophanol's effects on lipid accumulation and gene expression. Techniques included Oil Red O staining for lipid droplets, CCK-8 assays for cell viability, and quantitative real-time PCR (qRT-PCR) for gene expression analysis. They also used specific inhibitors (OSS-128167 for SIRT6, Compound C for AMPK) and small interfering RNA (si-SIRT6) to probe the signaling pathways.
  • In vivo studies: High-fat diet (HFD)-induced obese mice were used as a model. They also utilized fat-specific Sirtuin 6 knockout (SIRT6 FKO) mice to specifically assess SIRT6's role. Key measurements included body weight, fat mass, lean mass, food intake, glucose tolerance tests (GTT), insulin tolerance tests (ITT), energy expenditure analysis (using a Comprehensive Lab Animal Monitoring System), histological analysis of adipose tissue, and Western blotting for protein expression.

Datasets

Not discussed in the paper. The study primarily relies on experimental data generated from cell cultures and animal models.

Key Insights and Ideas

  • Chrysophanol as a "browning" agent: The study strongly suggests chrysophanol can induce "browning" of white adipose tissue (WAT), transforming it into a more metabolically active, brown-like state. This is a significant finding as it implies a potential strategy to increase energy expenditure from stored fat.
  • SIRT6-AMPK axis as the central player: The research pinpoints the SIRT6/AMPK signaling pathway as the critical mediator of chrysophanol's effects. This provides a specific molecular target for future drug development.
  • Dual action on fat: Chrysophanol not only inhibits lipid accumulation in adipocytes but also promotes lipolysis (fat breakdown) and fatty acid oxidation, further contributing to reduced fat mass.
  • SIRT6's essential role: The experiments with SIRT6 knockout mice clearly demonstrate that SIRT6 is indispensable for chrysophanol to exert its beneficial effects on weight management, thermogenesis, and insulin sensitivity.

Key Results

  • Chrysophanol significantly reduced body weight, fat mass, and improved insulin sensitivity in HFD-induced obese mice.
  • In vitro, chrysophanol inhibited lipid accumulation in 3T3-L1 adipocytes and increased the expression of genes involved in fatty acid oxidation and lipolysis.
  • Chrysophanol treatment led to increased oxygen consumption, carbon dioxide production, and heat production in obese mice, indicating enhanced thermogenesis.
  • In SIRT6 FKO mice, chrysophanol's ability to reduce body weight, increase thermogenesis, and improve insulin sensitivity was significantly blunted.
  • Inhibition of SIRT6 or AMPK pathways attenuated chrysophanol's beneficial effects on lipid accumulation and gene expression.

Limitations and Future Work

  • Mechanism of SIRT6 activation: While the study shows chrysophanol activates SIRT6, the precise upstream mechanism by which chrysophanol interacts with SIRT6 is not fully elucidated.
  • Long-term effects and human translation: The study was conducted in mice. Further research is needed to confirm these findings in longer-term studies and to assess the potential for human translation.
  • Adverse effects: While the paper mentions chrysophanol is effective without serious adverse events at the tested doses, comprehensive safety profiling would be necessary for clinical applications.
  • Sympathetic nervous system interaction: The authors suggest further investigation into whether chrysophanol increases heat production through pathways beyond the sympathetic nervous system.

The findings highlight chrysophanol and the SIRT6/AMPK pathway as promising targets for developing novel therapeutic strategies against obesity and associated metabolic disorders.

Summary updated

Abstract

Chrysophanol, a primary active ingredient of <i>Cassia mimosoides Linn</i> or <i>Rhei radix et rhizoma</i>, has various pharmacological properties, including anticancer, antidiabetic, and anti-inflammatory, as well as blood lipid regulation. However, whether chrysophanol can mitigate obesity, and its underlying mechanisms remains unclear. This study investigated whether chrysophanol effects energy metabolism in high-fat diet- (HFD-) induced obese mice and fat-specific Sirtuin 6- (SIRT6-) knockout (FKO) mice, targeting the SIRT6/AMPK signaling pathway in brown and white fat tissue. Our results showed that chrysophanol can effectively inhibit lipid accumulation in vitro and reduce mice's body weight, improve insulin sensitivity and reduced fat content of mice, and induce energy consumption in HFD-induced obese mice by activating the SIRT6/AMPK pathway. However, a treatment with OSS-128167, an SIRT6 inhibitor, or si-SIRT6, SIRT6 target specific small interfering RNA, in vitro blocked chrysophanol inhibition of lipid accumulation. Similar results were obtained when blocking the AMPK pathway. Moreover, in the HFD-induced obese model with SIRT6 FKO mice, histological analysis and genetic test results showed that chrysophanol treatment did not reduce lipid droplets and upregulated the uncoupling protein 1 (UCP1) expression. Rather, it upregulated the expression of thermogenic genes and activated white fat breakdown by inducing phosphorylation of adenosine 5'-monophosphate- (AMP-) activated protein kinase (AMPK), both in vitro and in vivo. OSS-128167 or si-SIRT6 blocked chrysophanol's upregulation of peroxisome proliferator-activated receptor-<i>γ</i> coactivator-1<i>α</i> (Pgc-1<i>α</i>) and Ucp1 expression. In conclusion, this study demonstrated that chrysophanol can activate brown fat through the SIRT6/AMPK pathway and increase energy consumption, insulin sensitivity, and heat production, thereby alleviating obesity and metabolic disorders.
BibTeX
@inproceedings{liu2020chrysophanol,
  author = {Xueying Liu and Zehong Yang and Huixuan Li and Wen Luo and Wentao Duan and Junmei Zhang and Zhangzhi Zhu and Min Liu and Saimei Li and Xiaoyi Xin and Hao‐Xiang Wu and Shaoxiang Xian and Meijing Liu and Changhui Liu and Chuangpeng Shen},
  title = {{Chrysophanol Alleviates Metabolic Syndrome by Activating the SIRT6/AMPK Signaling Pathway in Brown Adipocytes}},
  booktitle = {Oxidative},
  year = {2020},
  doi = {10.1155/2020/7374086},
}
Figure